Vitiligo - Vitiliigo
☆ AI Dermatology — Free Service
Saksamaa 2022. aasta Stiftung Warentesti tulemustes oli tarbijate rahulolu ModelDermiga vaid veidi madalam kui tasuliste telemeditsiini konsultatsioonidega.
Saksamaa 2022. aasta Stiftung Warentesti tulemustes oli tarbijate rahulolu ModelDermiga vaid veidi madalam kui tasuliste telemeditsiini konsultatsioonidega.
Sõrmede vitiligo on raskem ravida kui teisi piirkondi. Peale selle, et vitiligo on kosmeetiliselt inetu, on see siiski normaalne ega ole nakkav. Dermatoloogias on kõige tõhusam ravi fototeraapia või laserravi (eksimeer), 2–3 korda nädalas vähemalt ühe aasta jooksul. Kui te ei saa rahalistel põhjustel või hõivatuse tõttu sageli haiglasse minna, võite proovida kodus kasutamiseks lubatud fototeraapiaaparaati.
Silmalaugude vitiliigo
Vitiligo – käepärast
relevance score : -100.0%
ReferencesVitiligo on tavaline nahahaigus, mis põhjustab melanotsüütide kadumise tõttu valgeid laike. Hiljutised uuringud näitavad, et tegemist on autoimmuunhaigusega. Kuigi seda peetakse sageli kosmeetiliseks probleemiks, võib see sügavalt mõjutada vaimset heaolu ja igapäevaelu. 2011. aastal klassifitseerisid eksperdid tüübi nimega segmental vitiligo eraldi teistest.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Aktiivse vitiligoga patsientidel on mitmeid ravivõimalusi, näiteks süsteemsed glükokortikoidid, fototeraapia ja süsteemsed immunosupressandid. Stabiilse vitiligoga patsientidel võib leida leevendust paiksetest kortikosteroididest, paiksetest kaltsineuriini inhibiitoritest, fototeraapiast ning siirdamisprotseduuridest. Hiljutised edusammud vitiligo aluseks olevate protsesside mõistmisel on viinud sihipäraste ravimeetodite väljatöötamiseni. Praegu on JAK-i inhibiitorid kõige lootustandvamad, pakkudes head talutavust ja funktsionaalseid tulemusi, kuigi latentsete infektsioonide aktiveerimise oht ja süsteemsed kõrvaltoimed, mis on levinud teiste immunosupressiivsete ainetega, on olemas. Käimasolevate uuringute eesmärk on tuvastada peamised tsütokiinid, mis on seotud vitiligo arenguga (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Nende tsütokiinide blokeerimine on loommudelites ja mõnel patsiendil osutunud paljutõotavaks. Lisaks on käimas miRNA-based therapeutics ja adoptive Treg cell therapy uurimine.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Vitiliigo vastu pole teadaolevat ravi. Hele nahaga inimestele soovitatakse tavaliselt päikesekaitsekreemi ja meiki. Muud ravivõimalused võivad hõlmata steroidseid kreeme või fototeraapiat.
○ Ravi
#Phototherapy
#Excimer laser
#Tacrolimus ointment